

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 August 2025 (21.08.2025)



(10) International Publication Number
WO 2025/175067 A1

- (51) **International Patent Classification:**
A61K 31/381 (2006.01) *A61P 25/00* (2006.01)
- (21) **International Application Number:**
PCT/US2025/015881
- (22) **International Filing Date:**
14 February 2025 (14.02.2025)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/554,269 16 February 2024 (16.02.2024) US
- (71) **Applicant: SUMITOMO PHARMA AMERICA, INC.**
[US/US]; 84 Waterford Drive, Marlborough, Massachusetts
01752 (US).
- (72) **Inventors: HOPKINS, Seth Cabot;** c/o Sumitomo Pharma America, Inc., 84 Waterford Drive, Marlborough, Massachusetts 01752 (US). **GALLUPPI, Gerald R.;** c/o Sumitomo Pharma America, Inc., 84 Waterford Drive, Marlborough, Massachusetts 01752 (US).
- (74) **Agent: FREDERICKS, Kellie S.;** Heslin Rothenberg Farley & Mesiti, P.C., 5 Columbia Circle, Albany, New York 12203 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) **Title:** METHODS OF ADMINISTERING THE NEUROPSYCHIATRIC MEDICATION ULOTARONT BASED ON RENAL IMPAIRMENT

(57) **Abstract:** Neuropsychiatric medications, particularly ulotaront, and their use based on renal function.

WO 2025/175067 A1